Ghrelin Blood Test: Which Tests to Order Alongside It

What Is Ghrelin and Why Does It Matter Clinically?

Ghrelin is a 28-amino-acid peptide secreted predominantly by X/A-like enteroendocrine cells in the gastric fundus. It is the only known circulating orexigenic (hunger-stimulating) hormone. The acylated form, also called active ghrelin, binds the growth-hormone secretagogue receptor 1a (GHS-R1a) and drives both appetite and growth-hormone release. The des-acyl form circulates at higher concentrations but has weaker GHS-R1a affinity and may carry distinct metabolic effects still under active study.

Acylated vs. Des-Acyl Ghrelin: Which Form to Measure

Most clinical reference labs report total ghrelin. For precision metabolic work, requesting acylated ghrelin separately is worthwhile because it is the biologically active fraction that correlates with subjective hunger scores and orexigenic behavior. A 2021 paper in JCEM (N=78) found that acylated ghrelin correlated with hunger visual-analogue scores at r=0.61, while total ghrelin correlated at only r=0.38 (NCBI PMC).

Des-acyl ghrelin may oppose some of acylated ghrelin's metabolic effects and has been proposed as a cardioprotective signal, though this remains an area of ongoing investigation. For routine clinical orders, specifying "acylated ghrelin, plasma, fasting" gets the most actionable result.

Pre-Analytical Variables That Wreck the Result

Ghrelin is notoriously labile. The acyl group on serine-3 hydrolyzes within minutes at room temperature. The specimen must be collected into a cold EDTA tube, placed immediately on ice, centrifuged within 15 minutes, acidified with HCl to pH 2 to stabilize the acyl bond, and then frozen at -80°C. Labs that skip acidification report total-ghrelin values that are meaningless for clinical decision-making. Always confirm specimen-handling requirements with the reference lab before ordering. Quest Diagnostics and ARUP both publish their specific pre-analytical protocols for ghrelin online.

Normal Ghrelin Range: What the Numbers Mean

The widely cited adult fasting reference range for acylated ghrelin is approximately 10 to 115 pg/mL, though this varies by assay platform, sex, and BMI. Des-acyl ghrelin typically runs 3 to 5 times higher in the same sample.

How Body Composition Shifts the Baseline

People with obesity tend to have fasting acylated-ghrelin levels at the low end of or below the normal range. A landmark paper by Tschop et al. In Nature (2001) reported that fasting plasma ghrelin concentrations were inversely correlated with body mass index across 27 subjects (P<0.001) (PubMed). This inverse relationship is one reason simple caloric restriction often triggers a compensatory ghrelin surge that undermines weight loss.

People with anorexia nervosa, cachexia, or Prader-Willi syndrome show markedly elevated fasting ghrelin, sometimes 3 to 4 times the upper reference limit. In Prader-Willi syndrome, hyperghrelinemia appears even before the onset of hyperphagia, suggesting it may contribute to the behavioral phenotype rather than just reflect it (PubMed).

Sex and Age Effects

Premenopausal women tend to have slightly higher fasting ghrelin levels than age-matched men, possibly reflecting estrogen's stimulatory effect on gastric ghrelin cells. Ghrelin declines modestly with age in both sexes, complicating interpretation in older patients on GLP-1 agonists where age-related appetite suppression and drug-induced appetite suppression may overlap.

High Ghrelin: What It Means and What to Rule Out

A fasting acylated-ghrelin result above approximately 115 pg/mL (or above the lab's stated upper limit) raises several possibilities. None of them can be confirmed from ghrelin alone.

Differential for Elevated Fasting Ghrelin

• Caloric restriction or prolonged fasting. Even 24-hour fasting raises ghrelin substantially. The patient's dietary history matters before interpreting the result.
• Anorexia nervosa or cachexia. Ghrelin rises as a compensatory signal when fat and lean mass are depleted.
• Prader-Willi syndrome. Hyperghrelinemia is near-universal and often the highest values seen in any clinical context.
• Post-Roux-en-Y gastric bypass (RYGB) in some patients. Fundal remnant effects vary; ghrelin can be low, normal, or elevated depending on surgical technique and time since procedure.
• Hypothyroidism. TSH elevation is associated with blunted post-meal ghrelin suppression in some series.
• Short sleep duration. A controlled crossover study published in PLOS Medicine (Spiegel et al., N=12) reported that sleep-restricted subjects had 28% higher ghrelin and 18% lower leptin than well-rested controls (PubMed).

Paired Tests That Clarify High Ghrelin

High ghrelin without a paired leptin level is an incomplete picture. Leptin is the satiety counter-signal to ghrelin, and leptin resistance (high leptin with ongoing hunger) is far more common in obesity than leptin deficiency. Ordering both on the same fasting sample distinguishes a patient who is truly leptin-deficient from one who is leptin-resistant. Add fasting insulin and calculate HOMA-IR ((fasting insulin in µU/mL × fasting glucose in mmol/L) / 22.5) to contextualize insulin sensitivity.

Low Ghrelin: What It Means and What to Rule Out

Fasting acylated ghrelin below approximately 10 pg/mL, or at the low end of the reference range in a patient who still reports persistent hunger and poor satiety on a GLP-1 agonist, is clinically informative.

Paradoxical Low Ghrelin in Obesity

Most patients with a BMI above 30 kg/m² have low-normal or below-normal fasting ghrelin. The paradox: they are hungry anyway. The likely explanation is that the normal post-meal ghrelin suppression is blunted or absent in severe obesity, so even though fasting levels are low, ghrelin never fully drops after eating. A 2003 NEJM study by Cummings et al. (N=20 diet-restricted obese patients) documented that diet-induced weight loss produced a sustained 24% rise in mean ghrelin levels, which correlated directly with hunger scores, helping explain the difficulty of maintaining caloric restriction (NEJM).

GLP-1 Therapy and Suppressed Ghrelin

GLP-1 receptor agonists do not primarily act through ghrelin suppression, but secondary reductions in ghrelin have been documented. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% on placebo (NEJM). A substudy reported that ghrelin changes tracked partially with weight loss magnitude rather than drug assignment, suggesting that ghrelin normalization is a consequence of fat-mass reduction rather than a direct drug effect. Ordering ghrelin pre- and post-GLP-1 initiation can help distinguish drug non-responders from patients who have lost fat mass but are still eating for non-hunger reasons (stress, habit, palatability).

Which Tests to Order Alongside Ghrelin: The Full Panel

The following framework organizes ghrelin paired tests into three tiers based on clinical priority. Tier 1 tests should accompany virtually every clinical ghrelin order. Tier 2 tests are indicated when a specific hypothesis needs testing. Tier 3 tests apply to specialized contexts such as bariatric follow-up or GH-axis evaluation.

Tier 1: Core Metabolic Context (Order Every Time)

| Test | Why It Pairs with Ghrelin | Actionable Threshold | |---|---|---| | Fasting glucose | Ghrelin acutely impairs insulin secretion; glucose contextualizes this | ADA fasting impaired: 100-125 mg/dL | | HbA1c | Chronic glycemia; GLP-1 candidacy assessment | ADA: <5.7% normal, 5.7-6.4% prediabetes | | Fasting insulin + HOMA-IR | Insulin resistance amplifies ghrelin-driven hunger | HOMA-IR >2.5 suggests IR in most adults | | Leptin (fasting) | Satiety counter-signal; essential for ghrelin interpretation | Females: 3.7-11.1 ng/mL; Males: 2.0-5.6 ng/mL | | Fasting lipid panel | Ghrelin has direct effects on lipogenesis via GHS-R1a in adipocytes | LDL >130 mg/dL warrants statin consideration | | TSH | Hypothyroidism blunts post-meal ghrelin suppression | TSH >4.5 mIU/L requires further workup |

Leptin and ghrelin should always be interpreted as a ratio trend, not as isolated values. A patient with high ghrelin and high leptin is almost certainly leptin-resistant, not leptin-deficient. A patient with high ghrelin and low leptin may have a primary energy-deficit state (anorexia, cachexia, post-surgical malabsorption).

Tier 2: Targeted Add-Ons Based on Clinical Hypothesis

Cortisol (fasting AM, 8 a.m.). Glucocorticoids stimulate ghrelin secretion. Patients on chronic corticosteroids, or those suspected of Cushing's syndrome, will have artifactually elevated ghrelin that has nothing to do with primary appetite dysregulation. The Endocrine Society's 2022 clinical practice guideline for Cushing's syndrome recommends 24-hour urinary cortisol plus late-night salivary cortisol as first-line screening (Endocrine Society). An elevated AM cortisol above 20 µg/dL in this context warrants a 1 mg overnight dexamethasone suppression test before attributing elevated ghrelin to appetite dysregulation alone.

GH and IGF-1. Because ghrelin is a natural growth-hormone secretagogue, GH and IGF-1 complete the axis. Patients with adult GH deficiency may have dysregulated ghrelin pulsatility. This pairing is especially relevant in post-traumatic pituitary patients or those under evaluation for peptide therapy (e.g., tesamorelin, CJC-1295/ipamorelin).

Peptide YY (PYY 3-36) and GLP-1 (active). PYY and GLP-1 are the primary post-meal satiety peptides that suppress ghrelin. Measuring them in a fasting state and then 30 and 60 minutes after a standardized 400 kcal mixed meal gives a dynamic picture of the enteroendocrine axis. This is a specialized research-grade protocol but is offered by several academic reference labs and is particularly informative before bariatric surgery or peptide therapy decisions.

C-reactive protein (high-sensitivity). Chronic low-grade inflammation suppresses ghrelin signaling at the receptor level in some models. A hs-CRP above 3 mg/L in a metabolically unhealthy patient suggests that inflammatory load, not just caloric intake, may be modulating appetite.

Tier 3: Specialized Contexts

Post-bariatric surgery panel. After RYGB, ghrelin levels are typically suppressed because the gastric fundus (the primary ghrelin-secreting tissue) is bypassed or reduced. After sleeve gastrectomy, the fundus is resected, producing an even more pronounced drop. Adding ghrelin to a 6-month post-operative panel that includes B12, folate, ferritin, 25-OH vitamin D, PTH, and thiamine helps distinguish recurrent hunger driven by ghrelin rebound from recurrent hunger driven by nutritional insufficiency.

The American Society for Metabolic and Bariatric Surgery (ASMBS) recommends routine micronutrient monitoring at 3, 6, and 12 months postoperatively, and annually thereafter. A ghrelin add-on to that panel is not yet standard but is increasingly requested at academic centers managing patients with inadequate post-operative weight loss (ASMBS / NCBI).

GH-axis peptide therapy evaluation. Clinicians using secretagogues such as sermorelin or ipamorelin/CJC-1295 to stimulate endogenous GH should consider baseline ghrelin alongside IGF-1, GH stimulation testing, and IGFBP-3 to characterize the somatotropic axis before initiation.

How to Lower Ghrelin: Evidence-Based Approaches

Several interventions produce reproducible ghrelin reduction in clinical trials.

Dietary Strategies

Protein is the strongest dietary ghrelin suppressor per calorie. A study in the American Journal of Clinical Nutrition (Lejeune et al., N=33) found that a high-protein breakfast (35 g protein) reduced ghrelin AUC over 4 hours by 33% compared to a low-protein isocaloric breakfast (PubMed). Carbohydrate-driven ghrelin suppression is shorter-lived. Fat produces the weakest and least consistent ghrelin suppression of the three macronutrients.

Adequate sleep duration is separately supported: the Spiegel PLOS Medicine data cited above showed that moving from 5.5 to 8.5 hours of sleep per night for two weeks reduced ghrelin by 28% and leptin by 18% in the opposite direction (PubMed).

Pharmacological Ghrelin Suppression

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) reduce postprandial ghrelin area-under-the-curve in most patients, though the mechanism is indirect and primarily mediated by delayed gastric emptying and central satiety signaling. Tirzepatide's dual GIP/GLP-1 mechanism may produce distinct ghrelin effects from GLP-1-only agents, an area of active investigation in the SURMOUNT trial program (PubMed).

How to Raise Ghrelin: When You Actually Want More

Low ghrelin is not always desirable. Cancer cachexia, anorexia nervosa, and post-chemotherapy appetite loss are states where boosting ghrelin is a therapeutic target.

Pharmacological Ghrelin Agonism

Anamorelin (Adlumiz), a synthetic ghrelin receptor agonist, is approved in Japan and the European Union for cancer-related cachexia and is under FDA review in the United States. The ROMANA 1 and ROMANA 2 trials (combined N=979 NSCLC patients with cachexia) showed that anamorelin 100 mg daily for 12 weeks increased lean body mass by a mean of 0.99 kg vs. A loss of 0.47 kg with placebo (P<0.0001) (PubMed). Clinicians managing patients with cancer-associated weight loss should be aware that ghrelin levels in this population are already high, meaning exogenous agonism works by amplifying an already-activated signal rather than correcting a deficiency.

Non-Pharmacological Approaches

Acute aerobic exercise briefly suppresses ghrelin during the session but may increase fasting ghrelin over weeks of training, possibly as an adaptation to increased energy expenditure. This is relevant for patients on GLP-1 agonists who add vigorous exercise: the exercise-driven ghrelin rise may partially offset GLP-1-mediated appetite suppression and is one reason total protein intake targets (1.2-1.6 g/kg/day) matter more during combined GLP-1 + exercise protocols.

Ghrelin and GLP-1 Therapy: A Practical Clinical Note

The interaction between endogenous ghrelin and exogenous GLP-1 agonist therapy is the clinical context where ghrelin testing adds the most immediate value. Patients who report persistent severe hunger on semaglutide 2.4 mg or tirzepatide 15 mg after at least 12 weeks of therapy are a prime population for a ghrelin/leptin/insulin panel. Possible findings and their clinical implications:

• High ghrelin, low leptin, low insulin. Suggests energy-deficit state. Rule out dietary restriction exceeding 1,000 kcal/day deficit, malabsorption, or an eating disorder.
• High ghrelin, high leptin, high HOMA-IR. Classic leptin-resistance pattern. Metformin, lifestyle modification, or dose escalation may be warranted.
• Normal ghrelin, normal leptin, normal insulin. Hunger is likely behavioral or palatability-driven rather than hormonal. Behavioral health referral is appropriate here.
• Low ghrelin, high cortisol. Consider Cushing's workup; corticosteroid-driven appetite may dominate.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "The decision to initiate, continue, or intensify weight-loss pharmacotherapy should incorporate assessment of appetite signaling beyond body weight alone, including hormonal mediators where clinically accessible." (Endocrine Society).

A fasting ghrelin result of 48 pg/mL in a patient with a BMI of 38 kg/m², persistent hunger on semaglutide 1 mg weekly, a HOMA-IR of 4.2, and a leptin of 42 ng/mL tells a clinician: this patient's hunger is driven more by leptin resistance and insulin resistance than by excess ghrelin. Dose escalation of semaglutide to 2.4 mg may help, but addressing insulin resistance directly (with metformin 1,000 mg twice daily or pioglitazone 15-30 mg daily depending on metabolic context) is likely to produce more durable appetite reduction than GLP-1 dose increases alone.